Foot Locker is crashing after a big earnings miss (FL)

Foot Locker is down about 20% in premarket trading on Friday after releasing dismal second-quarter results. The sneaker retailer reported earnings of $0.39 a share, much lower than Wall Street’s estimates of $0.89. Revenue was also light, coming in at $1.7 billion, which was lower than the $1.8 billion that was expected by the Bloomberg consensus. Additionally, same-store sales slumped 6% versus a year ago. The second quarter results were dragged down by a $50 million pre-tax litigation charge related to a lawsuit regarding the company’s pension plans for former employees. During the quarter, the company opened 24 new stores, bucking the recent trend of retail store closures. Foot Locker… Read More

Continue Reading

Properly fitted dentures mean more self confidence

Marilyn Davidse, 73, a longtime denture wearer, endured years of discomfort before finding relief in customized dentures. Five years ago, Davidse bought a set of standard dentures at an Edmonton shopping centre. Within less than a year, two of the false teeth had fallen out—while Davidse was on holiday, no less—and the fit was so uncomfortable she sometimes couldn’t wear the dentures at all. “They weren’t lined up properly, and that’s why the teeth broke off, because they didn’t fit properly,” she says. To make matters worse, when she went back to the business that sold her the dentures to complain about the broken teeth and poor fit, she was… Read More

Continue Reading

Mylan and New York feds reach $465M settlement over EpiPen charges

An investigation into EpiPen manufacturer Mylan Inc. will see that New York gets $38.5 million returned to its coffers. That’s according to Attorney General Eric Schneiderman, who announced Thursday that New York — which led a coalition of states in an investigation against the Canonsburg, Pennsylvania-based drug company — has agreed to join a state-federal $465 million settlement. Federal authorities contend Mylan underpaid rebates owed to Medicaid for EpiPen products — an epinephrine auto-injector… …read more Source:: Pittsburgh Business News

Continue Reading